Search PubMed⌕ Search

Biomedical subjects

S Polakoff

Publications and source records attributed to S Polakoff.

At least 19 recordsLinked to original sources
PubMed1992

Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study.

BACKGROUND: Considerable evidence indicates that the lipophilic beta-blocker propranolol is useful in treating organically based aggression. This study looked at the efficacy of a more hydrophilic beta-blocker, nadolol, to treat aggression in chronic psychiatric inpatients. METHOD: Forty-one chronic psychiatric inpatients with an average of one aggressive outburst per week (defined by the Overt Aggression Scale [OAS]) were entered into a double-blind, placebo-controlled study lasting 17 weeks. The OAS was used to track aggression on a per-incident basis, while the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impressions scale (CGI) were used to track clinical status. RESULTS: Nadolol subjects showed a significant decline in frequency of aggression compared with controls (p = .026) and a significant decline in the BPRS total score (p = .007) and in the subfactors "hostility and suspicion," "negative symptoms," and "signs of hyperarousal/tension." There was no significant change in CGI "severity of illness" ratings between groups, although the nadolol group was significantly improved from baseline at every subsequent time period while the placebo group was unchanged throughout the study. CONCLUSION: Nadolol is of significant benefit in the treatment of aggression in chronic psychiatric inpatients. This drug does penetrate the brain over time, but the success of a drug whose primary locus of action is peripheral may implicate a bimodal mechanism of action, i.e., a role for the CNS and the soma in the maintenance of aggression.

Adult↗
PubMed1990

Reports of clinical hepatitis A from Public Health and hospital microbiology laboratories to the PHLS Communicable Disease Surveillance Centre during the period 1980-1988.

Clinical hepatitis, diagnosed as being caused by virus type A by tests for specific immunoglobulin M, has been reported from laboratories in England, Wales and Ireland since 1980. There were 25541 reports in the following 9 years, a yearly average of 2838. A 7-year cycle is suggested by peaks in the numbers of reports of 4502 in 1982 and 4167 in 1988 with a continuing rise in 1989. Contact with other cases of acute hepatitis was recorded for 3899 patients (15%) of which 2497 (64%) were in families, 258 (7%) were in schools, 94 (2%) were in institutions/hospitals, 197 (5%) were in the neighbourhood, while 140 (4%) were contacts at work or socially. A possible food source was recorded for 122 (3%) with shellfish being specified in 56 cases. Recent travel abroad was reported for 3692 patients (15%) of whom 3027 (82%) had visited areas of high prevalence for hepatitis A. About half of them had been to the Indian sub-continent, in strong contrast to visits abroad by the general population each year of which only 7% of the 22 million visits are to areas of high prevalence for hepatitis A. Association with the Indian sub-continent was particularly high for children.

Disease Outbreaks↗
PubMed1990

Public Health Laboratory Service surveillance of prophylaxis by specific hepatitis B immunoglobulin in England and Wales during the period 1975-1987.

Surveillance of specific hepatitis B prophylaxis given after accidental or sexual exposure was continued throughout the period 1975-1987 by keeping records of exposures and ascertaining acute attacks of hepatitis B by postal enquiry. Acute hepatitis B developed in 53 (0.6%) of 9370 recipients of prophylaxis; the highest rate (3.7%) was among 564 sexually exposed, 0.9% among 2056 accidentally inoculated and 0.2% among 5747 persons who had other skin or minor exposures affecting the mucous membranes. There were no cases among 1003 recipients whose exposures did not meet the criteria for prophylaxis. None of the 53 patients died and only one of the 44, for whom sickness records were completed, reported a severe attack. Comparisons of six attacks among 623 who had inoculation injuries with material tested for hepatitis 'e' antigen and antibody gave no indication of better protection by early prophylaxis or by a two-dose schedule.

Antibodies, Viral↗
PubMed1989

Chronic liver disease. A case control study of the effect of previous blood transfusion.

A means of assessing hepatitis NANB virus infection, via blood transfusion, as a cause of chronic liver disease was investigated in a hospital in each of two cities in England. Patients with chronic liver disease were matched for age and sex with other patients in the same hospital and histories taken included details of previous operations and blood transfusions; if these were within ten years of the study enquiries were made of hospital records officers. All positive histories were found correct, but about one third of previous transfusions had been omitted by both case and control patients. Sixty-seven male and 35 female patients with chronic liver disease and their controls were included in analyses. The only clear difference which emerged related to residence for more than a year in the Middle or Far East by male case- (40%) or control- (21%) patients (P less than 0.05). The exclusion of patients with this history left only 34 pairs in which five (15%) of the case patients and one (3%) of the control patients had a transfusion history: this difference was not statistically significant. Although the study results have shown no clear evidence of blood transfusion as a major cause of chronic liver disease in Britain, the study method, with sufficient numbers to allow analyses of newly diagnosed patients with confirmed transfusion histories, could be used to provide an ongoing assessment of the risk.

Adolescent↗
PubMed1988

Immunisation of neonates at high risk of hepatitis B in England and Wales: national surveillance.

The results of a voluntary programme of immunisation against hepatitis B in neonates at high risk (mother being positive for hepatitis B surface antigen and without hepatitis B e antibody or having had acute hepatitis B late in pregnancy) are reported. The programme was offered in England and Wales from November 1982. Passive immunisation alone was available in the first six months of life until 1985, after which infants received passive and active immunisation from birth; in addition, some infants received passive immunisation for six months followed by a course of hepatitis B vaccine. All but a few infants received the first immunising dose within 48 hours after birth. Blood samples for analysing markers of hepatitis B virus were available at 1 year from 147 of the 223 infants given passive immunisation, 54 of the 72 given passive followed by active immunisation, and 102 of the 155 given passive and active immunisation at birth. At 1 year 11 of the 127 (9%) infants given four or more doses of specific hepatitis B immunoglobulin were positive for hepatitis B surface antigen compared with four of the 20 given three or fewer doses; 11 had levels of hepatitis B surface antibody greater than 50 IU/l. Only one of the 54 infants given passive then active immunisation was positive for hepatitis B surface antigen at 1 year and four infants had low (less than or equal to 50 IU/l) levels of hepatitis B surface antibody. Four of the 102 infants who received passive and active immunisation at birth were positive for hepatitis B surface antigen. Two had received the fill course of vaccine, whereas in the other two vaccination was incomplete or unstated. In 79 of the 89 infants who received a complete course of vaccination the level of hepatitis B surface antibody was known, and 70 had levels at 1 year greater than 100 IU/1. Reactions to immunisation were not severe at any age. The incidence of side effects was 8% for the immunoglobulin, 11% for the vaccine, and 9% when immunoglobulin and vaccine were given together. Wider collaboration in the programme is requested.

England↗
PubMed1987

Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults.

We began open trials of beta-blockers, as adjunctive medication, in eight consecutive autistic adults. The immediate result across all patients was a rapid diminution in aggressivity (Ratey et al., 1987). As time on the drug increased, subtler changes in speech and socialization emerged. While results of open trials must be interpreted with caution, these changes were significant and lasting. We speculate that these effects may be the result of a lessening of the autistic individual's state of hyperarousal. As the individual becomes less anxious, defensive and dearousing behaviors are relinquished and more social and adaptive behaviors appear. There is a concomitant improvement in language, though it is unclear whether lost skills are recouped or new ones developed. Further research is indicated.

Adult↗
PubMed1987

Autism: the treatment of aggressive behaviors.

Eight consecutive cases of adults with the diagnosis of early infantile autism and who were treated with a betablocker are presented. Each had been on various and multiple drug, educational, and behavioral regimens to help control aggressive and self-abusive behavior. Most had been institutionalized from an early age, and a broad range of IQs and speech capacities are represented. Results show the betablockers to have a remarkable effect potentiating measurable diminution in previously intractable aggressive behavior and in many cases the decrease or withdrawal of their neuroleptic.

Adrenergic beta-Antagonists↗
PubMed1986

Acute hepatitis B in patients in Britain related to previous operations and dental treatment.

The frequency of transmission of hepatitis B virus infection from health service staff to patients was assessed from reports of confirmed cases of acute clinical hepatitis in 1980-3. During the four years 4505 reports (91% of the total) included replies to a question about recent operations; 153 patients (3.4%) had this history. Transfused blood or blood products were considered the source for 27 cases (0.06%). Eleven patients (0.02%) were infected in two clusters, both in cardiac surgery units; six were caused by a perfusion technician, who was a symptomless carrier, and five by a surgical registrar during the incubation period of an acute hepatitis B infection. The estimated average annual risk of a patient developing acute hepatitis B as part of a cluster caused by staff during surgical procedures was one in a million operations. For another 11 patients blood transfusion could not be excluded as a source. Where no association between surgery and hepatitis was found the incidence of a history, lay between 2.3 and 2.6%. The Hospital In-Patient Enquiry data showed that about 2.4% of the population had had operations in a six month period. These findings suggest that transmission of hepatitis B infection from staff to patients is rare in Britain and that the small risk could be eliminated by attention to measures to preserve asepsis and by immunising staff at risk.

Adolescent↗
PubMed1986

Beta-blockers in the severely and profoundly mentally retarded.

The authors present data from four different institutions from open clinical trials of propranolol in 19 mentally retarded patients with IQs less than 50. When customary forms of treatment had failed, propranolol was initiated. A table showing changes in the patients' behavior is included. Twelve patients demonstrated a pronounced improvement in self-abusive and aggressive behavior, four made moderate gains, and three were considered unchanged. The authors postulate that at least some aspects of the behavioral improvement were due to the peripheral anxiolytic action of the beta-blockers. Contrary to other reports of using higher doses (greater than 520 mg/day range), the authors used a mean dose of 120 mg/day and consider the duration of time spent on the medication as a crucial factor in its effectiveness.

Adrenergic beta-Antagonists↗
PubMed1985

Nadolol as a treatment for akathisia.

The authors present three cases of patients with neuroleptic-induced akathisia who were successfully treated with nadolol, a peripherally acting beta blocker. They discuss the potential implications of this finding.

Adult↗
PubMed1979

Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines.

In children aged 15--16 years receiving routine reinforcement tetanus immunisation, adsorbed vaccine caused more severe and more frequent local reactions than did plain formol toxoid, and a higher incidence of pyrexia. The incidence of swelling and erythema at the inoculation site increased with serum antitoxin titre at the time of inoculation, whereas pain and tenderness were related to the presence of the aluminium hydroxide adjuvant. Both vaccines gave satisfactory antibody responses over a 5-month observation period; plain formol toxoid induced higher mean titres than did the adsorbed vaccine. It is recommended that plain and not adsorbed vaccine be used when reinforcement of immunity to tetanus alone is desired.

Adolescent↗